The human liver model market size has grown rapidly in recent years. It will grow from $2.07 billion in 2023 to $2.33 billion in 2024 at a compound annual growth rate (CAGR) of 12.7%. The growth observed in the historical period can be attributed to the needs in drug development, advancements in biotechnology, alternatives to animal testing, the increasing prevalence of liver diseases, and regulatory requirements.
The human liver model market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The anticipated growth in the forecast period can be attributed to the integration of AI and machine learning, the development of patient-derived liver models, breakthroughs in bioengineering, requirements for drug safety and toxicity testing, and the adoption of virtual clinical trials. Major trends expected in the forecast period include the integration of multi-organ models, innovations in 3D bioprinting, increased capability for high-throughput screening, improvements in vascularization and blood flow, and a heightened focus on ethical and regulatory compliance.
The growth of the human liver model market is anticipated to be driven by the increasing incidence of liver disease. Liver disease encompasses various disorders that affect the proper functioning of the liver. The emerging area of research involving human liver models holds the potential to enhance understanding of liver diseases and improve drug development. Consequently, the escalating cases of liver diseases are fostering the expansion of the human liver model market. For instance, in September 2022, Caner Australia reported approximately 2,905 new cases of liver cancer diagnosed in Australia in 2022, highlighting the significance of addressing liver-related health concerns. The rising prevalence of liver disease underscores the crucial role of human liver models in advancing medical research and therapeutic strategies.
The growth of the human liver model market is further expected to be propelled by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, treatments, or drugs in humans, frequently employ human liver models to simulate drug metabolism and assess hepatotoxicity in the context of pharmaceutical development. As of May 2023, there are 452,604 registered clinical trials globally, signifying a substantial increase from previous counts. The surge in clinical trials emphasizes the growing demand for human liver models in facilitating robust research practices and advancing drug discovery initiatives.
A prominent trend in the human liver model market is the focus on product innovation by major companies. Companies operating in this market are actively engaged in developing innovative products to enhance their market positioning. In April 2023, LifeNet Health Life Sciences introduced TruVivo, a groundbreaking liver system composed entirely of human cells. TruVivo represents a 2D+ solution that combines the robust data associated with 3D models with the flexibility and simplicity of a 2D model, offering a significant advancement in liver research and drug development.
Major players in the human liver model market are directing their efforts toward the development of advanced systems, particularly single-organ higher throughput (HT) systems. These innovative systems aim to improve the adoption of predictive human liver models and provide a competitive advantage. For instance, in February 2023, UK-based organ-on-a-chip company CN Bio launched PhysioMimix with Liver-48 plate, a single-organ higher throughput (HT) system designed to overcome challenges in the adoption of predictive human liver models for drug discovery. The Liver-48 plate, a multi-chip consumable, facilitates larger-scale comparative studies on drug disposition, efficacy, and safety.
In September 2021, Sweden-based life science company BICO acquired HUREL Corporation for $2.5 million. This acquisition positions BICO to expand its offerings with liver co-culture models and assays, catering to the diverse needs of customers. HUREL Corporation, based in the United States, specializes in providing microfluidic solutions, cell culture technologies, and liver models.
Major companies operating in the human liver model market report are Corning Incorporated, EISCO Scientific LLC, BioIVT LLC, Cyprotex PLC, Emulate Inc., Cellink AB, Strand Life Sciences Pvt Ltd., Nortis Inc., InSphero AG, CN Bio Innovations Ltd., TissUse GmbH, Ascendance Biotechnology Inc., HemoShear Therapeutics Inc., Cyfuse Biomedical KK, Cyfuse Biomedical, MIMETAS BV, Bio Innovations, Biopredic International Sarl, ZenBio, Hurel Corporation, Regenovo, Pandorum, Organovo Holdings Inc., BICO Group, Hepregen Corporation, Kirkstall Ltd., HepaLife Technologies Inc., Cellaïon SA.
North America was the largest region in the human liver model market in 2023. The regions covered in the human liver model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human liver model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary product types of human liver models include liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. Liver organoids are 3D structures generated from stem cells that self-organize through mechanisms similar to those in vivo. These models find applications in education, drug discovery, and other fields, and are employed by research institutes, pharmaceutical companies, and other entities.
The human liver model market research report is one of a series of new reports that provides human liver model market statistics, including human liver model industry global market size, regional shares, competitors with a human liver model market share, detailed human liver model market segments, market trends and opportunities, and any further data you may need to thrive in the human liver model industry. This human liver model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human liver model market consists of sales of 3B scientific liver and prime baker fiber liver model. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The human liver model market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The anticipated growth in the forecast period can be attributed to the integration of AI and machine learning, the development of patient-derived liver models, breakthroughs in bioengineering, requirements for drug safety and toxicity testing, and the adoption of virtual clinical trials. Major trends expected in the forecast period include the integration of multi-organ models, innovations in 3D bioprinting, increased capability for high-throughput screening, improvements in vascularization and blood flow, and a heightened focus on ethical and regulatory compliance.
The growth of the human liver model market is anticipated to be driven by the increasing incidence of liver disease. Liver disease encompasses various disorders that affect the proper functioning of the liver. The emerging area of research involving human liver models holds the potential to enhance understanding of liver diseases and improve drug development. Consequently, the escalating cases of liver diseases are fostering the expansion of the human liver model market. For instance, in September 2022, Caner Australia reported approximately 2,905 new cases of liver cancer diagnosed in Australia in 2022, highlighting the significance of addressing liver-related health concerns. The rising prevalence of liver disease underscores the crucial role of human liver models in advancing medical research and therapeutic strategies.
The growth of the human liver model market is further expected to be propelled by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, treatments, or drugs in humans, frequently employ human liver models to simulate drug metabolism and assess hepatotoxicity in the context of pharmaceutical development. As of May 2023, there are 452,604 registered clinical trials globally, signifying a substantial increase from previous counts. The surge in clinical trials emphasizes the growing demand for human liver models in facilitating robust research practices and advancing drug discovery initiatives.
A prominent trend in the human liver model market is the focus on product innovation by major companies. Companies operating in this market are actively engaged in developing innovative products to enhance their market positioning. In April 2023, LifeNet Health Life Sciences introduced TruVivo, a groundbreaking liver system composed entirely of human cells. TruVivo represents a 2D+ solution that combines the robust data associated with 3D models with the flexibility and simplicity of a 2D model, offering a significant advancement in liver research and drug development.
Major players in the human liver model market are directing their efforts toward the development of advanced systems, particularly single-organ higher throughput (HT) systems. These innovative systems aim to improve the adoption of predictive human liver models and provide a competitive advantage. For instance, in February 2023, UK-based organ-on-a-chip company CN Bio launched PhysioMimix with Liver-48 plate, a single-organ higher throughput (HT) system designed to overcome challenges in the adoption of predictive human liver models for drug discovery. The Liver-48 plate, a multi-chip consumable, facilitates larger-scale comparative studies on drug disposition, efficacy, and safety.
In September 2021, Sweden-based life science company BICO acquired HUREL Corporation for $2.5 million. This acquisition positions BICO to expand its offerings with liver co-culture models and assays, catering to the diverse needs of customers. HUREL Corporation, based in the United States, specializes in providing microfluidic solutions, cell culture technologies, and liver models.
Major companies operating in the human liver model market report are Corning Incorporated, EISCO Scientific LLC, BioIVT LLC, Cyprotex PLC, Emulate Inc., Cellink AB, Strand Life Sciences Pvt Ltd., Nortis Inc., InSphero AG, CN Bio Innovations Ltd., TissUse GmbH, Ascendance Biotechnology Inc., HemoShear Therapeutics Inc., Cyfuse Biomedical KK, Cyfuse Biomedical, MIMETAS BV, Bio Innovations, Biopredic International Sarl, ZenBio, Hurel Corporation, Regenovo, Pandorum, Organovo Holdings Inc., BICO Group, Hepregen Corporation, Kirkstall Ltd., HepaLife Technologies Inc., Cellaïon SA.
North America was the largest region in the human liver model market in 2023. The regions covered in the human liver model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human liver model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary product types of human liver models include liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. Liver organoids are 3D structures generated from stem cells that self-organize through mechanisms similar to those in vivo. These models find applications in education, drug discovery, and other fields, and are employed by research institutes, pharmaceutical companies, and other entities.
The human liver model market research report is one of a series of new reports that provides human liver model market statistics, including human liver model industry global market size, regional shares, competitors with a human liver model market share, detailed human liver model market segments, market trends and opportunities, and any further data you may need to thrive in the human liver model industry. This human liver model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human liver model market consists of sales of 3B scientific liver and prime baker fiber liver model. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Human Liver Model Market Characteristics3. Human Liver Model Market Trends and Strategies32. Global Human Liver Model Market Competitive Benchmarking33. Global Human Liver Model Market Competitive Dashboard34. Key Mergers and Acquisitions in the Human Liver Model Market
4. Human Liver Model Market - Macro Economic Scenario
5. Global Human Liver Model Market Size and Growth
6. Human Liver Model Market Segmentation
7. Human Liver Model Market Regional and Country Analysis
8. Asia-Pacific Human Liver Model Market
9. China Human Liver Model Market
10. India Human Liver Model Market
11. Japan Human Liver Model Market
12. Australia Human Liver Model Market
13. Indonesia Human Liver Model Market
14. South Korea Human Liver Model Market
15. Western Europe Human Liver Model Market
16. UK Human Liver Model Market
17. Germany Human Liver Model Market
18. France Human Liver Model Market
19. Italy Human Liver Model Market
20. Spain Human Liver Model Market
21. Eastern Europe Human Liver Model Market
22. Russia Human Liver Model Market
23. North America Human Liver Model Market
24. USA Human Liver Model Market
25. Canada Human Liver Model Market
26. South America Human Liver Model Market
27. Brazil Human Liver Model Market
28. Middle East Human Liver Model Market
29. Africa Human Liver Model Market
30. Human Liver Model Market Competitive Landscape and Company Profiles
31. Human Liver Model Market Other Major and Innovative Companies
35. Human Liver Model Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Human Liver Model Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on human liver model market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for human liver model? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Product: Liver Organoids; Liver-On-A-Chip; 2D Models; Animal Models; 3D Bioprinting
2) By Application: Educational; Drug Discovery; Other Applications
3) By End-users: Research Institutes; Pharmaceutical Companies; Other End-users
Key Companies Mentioned: Corning Incorporated; EISCO Scientific LLC; BioIVT LLC; Cyprotex plc; Emulate Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Corning Incorporated
- EISCO Scientific LLC
- BioIVT LLC
- Cyprotex plc
- Emulate Inc.
- Cellink AB
- Strand Life Sciences Pvt Ltd.
- Nortis Inc.
- InSphero AG
- CN Bio Innovations Ltd.
- TissUse GmbH
- Ascendance Biotechnology Inc.
- HemoShear Therapeutics Inc.
- Cyfuse Biomedical KK
- Cyfuse Biomedical
- MIMETAS BV
- Bio Innovations
- Biopredic International Sarl
- ZenBio
- Hurel Corporation
- Regenovo
- Pandorum
- Organovo Holdings Inc.
- BICO Group
- Hepregen Corporation
- Kirkstall Ltd.
- HepaLife Technologies Inc.
- Cellaïon SA.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | February 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 2.33 Billion |
Forecasted Market Value ( USD | $ 3.79 Billion |
Compound Annual Growth Rate | 12.9% |
Regions Covered | Global |
No. of Companies Mentioned | 28 |